Phase III study of sugemalimab in locally advanced/unresectable non-small cell lung cancer meets its primary endpoint

In the GEMSTONE-301 study, use of the investigational anti-PD-L1 monoclonal antibody in patients without disease progression after chemoradiotherapy was associated with prolonged progression-free survival [no details reported]. A new Drug Application is planned.

Source:

Biospace Inc.